Clinical Watch: May 2019

June 14, 2019

In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a new biologic for plaque psoriasis and review the albumin-lowering effect of dapagliflozin. Finally, we review claims data to identify potential implications of a new psoriasis treatment.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Flipbook
Conduent HSP Payer Suite Earns Leadership Ranking in NelsonHall’s Healthcare Commercial Payer BPS Report
Conduent HSP Payer Suite Earns Leadership Ranking in NelsonHall’s Healthcare Commercial Payer BPS Report

Conduent was recognized as a leader in the NelsonHall Healthcare Commercial Payer BPS report, which examine...

Next Article
Three Ways Hospitals can Use Data to Achieve and Sustain Quality Improvement
Three Ways Hospitals can Use Data to Achieve and Sustain Quality Improvement

How do you measure quality in healthcare? It's a question that is top of mind in an industry where quality ...